6533b837fe1ef96bd12a1e49
RESEARCH PRODUCT
Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study
Marianna SillettaDelia De LisiLuciano StumboGiuseppe BadalamentiG. MalteseAnna Maria FrezzaSantini DanieleMariella Spalato CerusoLinda CerboneTonini GiuseppeVincenzi Brunosubject
Malemedicine.medical_treatmentSoft Tissue NeoplasmsDioxoleKaplan-Meier EstimateGastroenterologyLiver Function TestsRetrospective StudieTetrahydroisoquinolinesTetrahydroisoquinolineTrabectedinMultidisciplinarybiologymedicine.diagnostic_testLiver Function TestSoft tissue sarcomaAlanine TransaminaseSarcomaMiddle AgedLiverFemaleSarcomamedicine.drugHumanAdultmedicine.medical_specialtyDioxolesdigestive systemArticleDisease-Free SurvivalDrug Administration ScheduleTransaminaseInternal medicinemedicineHumansAspartate AminotransferasesSoft Tissue NeoplasmAntineoplastic Agents AlkylatingRetrospective StudiesAgedChemotherapybusiness.industryRetrospective cohort studyAspartate Aminotransferasemedicine.diseasedigestive system diseasesSurgeryAlanine transaminasebiology.proteinbusinessLiver function testsAdult; Aged; Alanine Transaminase; Antineoplastic Agents Alkylating; Aspartate Aminotransferases; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; MultidisciplinaryTrabectedindescription
AbstractElevation in liver transaminases is common in patients treated with the marine antitumor agent trabectedin. However, the impact of trabectedin-related transaminase elevations on treatment outcomes is unclear. This retrospective study investigated the correlation between liver tests abnormalities and treatment outcomes in patients with unresectable advanced or metastatic soft tissue sarcomas (STS) treated with trabectedin 1.5 mg/m2 once every 3 weeks at three reference centers in Italy. The effect of grade 3/4 elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) during the first two cycles and at any time during trabectedin treatment on progression-free survival (PFS) and overall survival (OS) were analyzed. Liver tests abnormalities during the first two cycles of chemotherapy or at any time during trabectedin treatment did not significantly affect PFS or OS. Nor were survival outcomes significantly different in the subgroups of patients with or without ALT/AST increases or with ALT/AST elevations ≥15 × the upper limit of normal (ULN) versus those with ALT/AST elevation <15 × ULN. Although liver tests abnormalities are common in patients treated with trabectedin, elevations in ALT and AST are usually transient, occur during the first two cycles of treatment and do not appear to affect survival.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-08-03 |